These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28917334)

  • 1. [Checkpoint inhibitors, the perspectives for elderly patients].
    Landre T; Karaoud F; Taleb C
    Soins Gerontol; 2017; 22(127):30-33. PubMed ID: 28917334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].
    Gaultier De Saint Basile H; Poisson C; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Tartour E; De Guillebon E
    Bull Cancer; 2018 Dec; 105(12):1202-1208. PubMed ID: 30471959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
    Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
    Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
    [No Abstract]   [Full Text] [Related]  

  • 4. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
    Colombo MP
    Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the toxicities of checkpoint inhibitors in older patients with cancer.
    Alkharabsheh O; Kannarkatt P; Kannarkatt J; Karapetyan L; Laird-Fick HS; Al-Janadi A
    J Geriatr Oncol; 2018 Sep; 9(5):451-458. PubMed ID: 29567089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.
    Wang GX; Kurra V; Gainor JF; Sullivan RJ; Flaherty KT; Lee SI; Fintelmann FJ
    Radiographics; 2017; 37(7):2132-2144. PubMed ID: 29131763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumour assessment criteria for immune checkpoint inhibitors].
    Wasielewski E; Cortot AB
    Rev Mal Respir; 2018 Oct; 35(8):828-845. PubMed ID: 30166076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Older Adults: A Checkpoint to Palliation?
    Elias R; Odejide O
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e110-e120. PubMed ID: 31099630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Older Adults with Cancer.
    Godby RC; Johnson DB; Williams GR
    Curr Oncol Rep; 2019 May; 21(7):56. PubMed ID: 31065907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.
    Fessas P; Possamai LA; Clark J; Daniels E; Gudd C; Mullish BH; Alexander JL; Pinato DJ
    Immunology; 2020 Feb; 159(2):167-177. PubMed ID: 31646612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictable toxicities with futures immunotherapies or combinations].
    Mogenet A; Tomasini P; Greillier L; Barlesi F
    Bull Cancer; 2020 Oct; 107(10):1069-1078. PubMed ID: 32977938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Immunotherapy in Older Patients.
    Marrone KA; Forde PM
    Cancer J; 2017; 23(4):219-222. PubMed ID: 28731944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of immune checkpoint inhibitors-induced liver toxicity in cancer].
    Lebossé F; Bancel B; Levrero M; Merle P
    Bull Cancer; 2020 Oct; 107(10):1056-1068. PubMed ID: 32951849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition.
    Restrepo CR; Field DH; Kim AY
    J Vasc Interv Radiol; 2020 Nov; 31(11):1740-1744.e9. PubMed ID: 33019993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
    Brahmer JR; Lacchetti C; Thompson JA
    J Oncol Pract; 2018 Apr; 14(4):247-249. PubMed ID: 29517954
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune checkpoint inhibitors and cardiovascular toxicity.
    Lyon AR; Yousaf N; Battisti NML; Moslehi J; Larkin J
    Lancet Oncol; 2018 Sep; 19(9):e447-e458. PubMed ID: 30191849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach.
    Khan Z; Hammer C; Guardino E; Chandler GS; Albert ML
    Genome Med; 2019 Jun; 11(1):39. PubMed ID: 31221204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology.
    Varricchi G; Galdiero MR; Tocchetti CG
    Circulation; 2017 Nov; 136(21):1989-1992. PubMed ID: 29158212
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of immunotherapy toxicities in older adults.
    Bhandari S; Gill AS; Perez CA; Jain D
    Semin Oncol; 2018 Aug; 45(4):226-231. PubMed ID: 30446167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint inhibitor-induced uveitis: a case series.
    Conrady CD; Larochelle M; Pecen P; Palestine A; Shakoor A; Singh A
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):187-191. PubMed ID: 29080102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.